Literature DB >> 10689787

Use of CpG DNA for enhancing specific immune responses.

H L Davis1.   

Abstract

CpG ODN, owing to its wide range of immunostimulatory effects has been found to be a potent Th1-type adjuvant that is effective with virtually any type of antigen, although responses are less impressive with PS than protein antigens. The use of CpG ODN as an adjuvant may allow the development of vaccines against a wider range of diseases, which could include therapeutic vaccines for chronic infections or cancer, effective pediatric vaccines for newborns, and easily delivered mucosal vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689787     DOI: 10.1007/978-3-642-59672-8_12

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  6 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge.

Authors:  T D Crabtree; L Jin; D P Raymond; S J Pelletier; C W Houlgrave; T G Gleason; T L Pruett; R G Sawyer
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  CpG enhances the immunogenicity of heterologous DNA-prime/protein-boost vaccination with the heavy chain myosin of Brugia malayi in BALB/c mice.

Authors:  Jyoti Gupta; Manisha Pathak; Sweta Misra; Shailja Misra-Bhattacharya
Journal:  Parasitol Res       Date:  2019-05-08       Impact factor: 2.289

4.  Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2009-11-13       Impact factor: 3.641

5.  DNA containing CpG motifs induces angiogenesis.

Authors:  Mei Zheng; Dennis M Klinman; Malgorzata Gierynska; Barry T Rouse
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

6.  Advances in immunomodulating therapy of HBV infection.

Authors:  Chee-Kin Hui; George Kk Lau
Journal:  Int J Med Sci       Date:  2005-01-05       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.